The reason for the discrepancy between the findings on the MAP3K19 inhibitor in the murine models of fibrosis and emphysema and that of our findings in the asthma murine model using the MAP3K19 knockout mouse is unknown; however, there are differences between the asthma pathology focused on bronchial epithelial cells and those of the previous reports focused on macrophages and fibroblasts. Here, MAP3K19 is linked to asthma.